For Immediate Release NEW HUMAN DATA STRENGTHENS BIOLOGICAL RATIONALE FOR DMX-200 IN FSGS Highlights • New data presented at Kidney Week 2026 provides additional biological evidence supporting the 1 2 inflammatory mechanism of action of DMX-200 which targets CCR2 in FSGS • Independent...
New Data Supports Biological Rationale for DMX-200 in FSGS
Filed with ASX · · 17 pages · English
Release
Earlier from Dimerix
- 2026 AGM Notice of Meeting, Letter of Access and Proxy Form
- Dimerix Announces Board Chair Transition
- DMX-200 First 100 Patients Complete Phase 3 Trial Treatment
- Dimerix at Canaccord Drug & Device and Ignite Conferences
- First Patient Reaches Four Years in DMX-200 Clinical Program
